Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2022 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share (the "Shares")
Symbol
ACRV on Nasdaq
Shares outstanding
31,306,673
Price per share
$2.61
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
17,481,015
Total reported value
$32,591,808
% of total 13F portfolios
0%
Share change
-321,815
Value change
+$816,603
Number of holders
46
Price from insider filings
$2.61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sands Capital Life Sciences Pulse Fund II, L.P. 6.8% $2,823,065 2,122,605 Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2025
CITADEL ADVISORS LLC 5.5% +12% $3,116,579 +$326,709 1,721,867 +12% Kenneth Griffin 14 Nov 2025

As of 30 Sep 2025, 46 institutional investors reported holding 17,481,015 shares of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV). This represents 56% of the company’s total 31,306,673 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 27% 8,340,508 0% 0.19% $15,096,319
Sands Capital Alternatives, LLC 6.8% 2,122,605 0% 0.84% $3,841,915
CITADEL ADVISORS LLC 4.9% 1,541,326 -19% 0% $2,789,800
WELLINGTON MANAGEMENT GROUP LLP 2.8% 888,130 0% 0% $1,607,515
UBS Group AG 2.2% 683,218 +150058% 0% $1,236,624
VANGUARD GROUP INC 2% 626,148 +5.5% 0% $1,133,327
RENAISSANCE TECHNOLOGIES LLC 2% 623,400 +22% 0% $1,128,354
ACORN CAPITAL ADVISORS, LLC 1.3% 405,237 0% 0.37% $733,479
BlackRock, Inc. 1.1% 330,957 -19% 0% $599,032
TWO SIGMA INVESTMENTS, LP 1% 319,205 +76% 0% $577,761
JANE STREET GROUP, LLC 0.92% 289,248 -7.2% 0% $523,539
GEODE CAPITAL MANAGEMENT, LLC 0.61% 192,033 +17% 0% $347,717
MILLENNIUM MANAGEMENT LLC 0.59% 185,234 -37% 0% $335,274
MARSHALL WACE, LLP 0.48% 149,715 -17% 0% $270,984
TWO SIGMA ADVISERS, LP 0.44% 136,500 +319% 0% $247,065
Squarepoint Ops LLC 0.33% 104,324 -32% 0% $188,826
ACADIAN ASSET MANAGEMENT LLC 0.29% 92,004 0% $165,000
STATE STREET CORP 0.21% 67,145 0% 0% $121,532
MORGAN STANLEY 0.18% 57,160 -9.3% 0% $103,460
ALGERT GLOBAL LLC 0.14% 44,648 0% $81,000
NORTHERN TRUST CORP 0.13% 42,166 -9.9% 0% $76,321
XTX Topco Ltd 0.11% 35,955 -66% 0% $65,079
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.07% 22,900 0% 0% $41,449
BAKER BROS. ADVISORS LP 0.07% 22,809 0% 0% $41,284
BARCLAYS PLC 0.06% 19,965 -4.6% 0% $36,137

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 17,481,015 $32,591,808 +$816,603 $1.81 46
2025 Q2 17,802,633 $21,184,501 -$10,332,845 $1.19 52
2025 Q1 22,517,048 $45,710,971 -$2,113,905 $2.03 60
2024 Q4 23,250,351 $139,966,170 -$971,333 $6.02 60
2024 Q3 22,960,755 $160,725,841 -$2,679,680 $7.00 51
2024 Q2 23,451,873 $136,019,162 +$47,352,607 $5.80 51
2024 Q1 15,245,438 $109,005,307 +$3,446,852 $7.15 45
2023 Q4 10,678 $52,536 $4.92 1
2023 Q3 15,093,861 $144,297,383 -$326,020 $9.56 43
2023 Q2 15,126,531 $196,038,266 -$1,147,223 $12.96 40
2023 Q1 15,216,182 $191,059,731 +$6,824,904 $12.69 39
2022 Q4 14,483,960 $165,920,957 +$165,375,910 $11.52 17